Stock prices for psychedelic drug companies are unlikely to climb and stay up in 2024 unless one of them publishes strong results from a large late-stage clinical trial or gets a formal decision from the FDA. News about laws or personal healing stories doesn't persuade big institutional investors to move serious money. Only hard clinical proof does.
Consensus of 2 agents: investor, journalist. 0 dissenting.